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OBJECTIVE—Inducing human -cell growth while enhancing
function is a major goal in the treatment of diabetes. Parathyroid
hormone–related protein (PTHrP) enhances rodent -cell growth
and function through the parathyroid hormone-1 receptor
(PTH1R). Based on this, we hypothesized that PTH1R is ex-
pressed in human -cells and that PTHrP has the potential to
enhance human -cell proliferation and/or function.
RESEARCH DESIGN AND METHODS—PTH1R expression,
-cell proliferation, glucose-stimulated insulin secretion (GSIS),
and expression of differentiation and cell-cycle genes were
analyzed in human islets transduced with adenoviral PTHrP
constructs or treated with PTHrP peptides. The effect of overex-
pression of late G1/S cell cycle molecules was also assessed on
human -cell proliferation.
RESULTS—We found that human -cells express PTH1R. More
importantly, overexpression of PTHrP causes a signiﬁcant ap-
proximately threefold increase in human -cell proliferation.
Furthermore, the amino terminus PTHrP(1-36) peptide is sufﬁ-
cient to increase replication as well as expression of the late G1/S
cell-cycle proteins cyclin E and cyclin-dependent kinase 2 (cdk2)
in human islets. Notably, PTHrP(1-36) also enhances GSIS.
Finally, overexpression of cyclin E alone, but not cdk2, augments
human -cell proliferation, and when both molecules are ex-
pressed simultaneously there is a further marked synergistic
increase in replication.
CONCLUSIONS—PTHrP(1-36) peptide enhances human -cell
proliferation as well as function, with associated upregulation of
two speciﬁc cell-cycle activators that together can induce human
-cell proliferation several fold. The future therapeutic potential
of PTHrP(1-36) for the treatment of diabetes is especially relevant
given the complementary therapeutic efﬁcacy of PTHrP(1-36) in
postmenopausal osteoporosis. Diabetes 59:3131–3138, 2010
L
oss of functional pancreatic -cells is the ultimate
cause of both type 1 and type 2 diabetes. There-
fore, ﬁnding ways to maintain or increase pancre-
atic -cell growth and function is essential in the
long-term treatment of this disease. Many studies over the
last decades have shown that adult human -cells retain
the capacity to proliferate, in vivo (1) and in vitro (2,3),
providing impetus to search for factors that can further
enhance -cell proliferation without negatively impacting
their function.
Although several growth factors enhance rodent -cell
proliferation and function (4), very few have been tested
on adult human -cells. In this regard, PTHrP, an auto-
crine/paracrine factor that is expressed in almost every
tissue in the body, including the endocrine pancreas (5),
has beneﬁcial effects on both -cell growth and function in
rodents. PTHrP overexpression in the -cell of transgenic
mice leads to increased -cell proliferation, -cell hyper-
plasia with concomitant hyperinsulinemia and hypoglyce-
mia, improved glucose tolerance, and enhanced GSIS
(6–8).
PTHrP is directed into the secretory pathway through its
signal peptide (SP) and can be targeted to the nucleus
through its nuclear localization signal. It undergoes post-
translational processing to form amino terminus (1-36),
mid-region (38-94), and COOH-terminal (107-171) frag-
ments. PTHrP mutants that lack SP fail to be secreted.
PTHrP signals through a seven-transmembrane G-protein
coupled receptor, PTH1R, which recognizes the amino
terminus PTHrP peptide (9). PTH1R is expressed in rodent
-cells and also in rodent -cell lines (8,10,11). Several
in vitro studies have shown that the amino-terminal
PTHrP(1-36) peptide, through its receptor, is sufﬁcient to
enhance rodent -cell proliferation as well as insulin
expression and GSIS (8,11,12). Thus, PTHrP enhances
both replication and function in primary rodent -cells.
PTHrP is also expressed in human islets and in almost
100% of human insulinomas (5,13,14). However, whether
PTH1R is expressed in human islets or in the human -cell
is not known. More importantly, it is unknown whether
PTHrP can have beneﬁcial effects on human -cells. Based
on extensive studies in rodent islets, we hypothesize that
the PTHrP/PTH1R system has the potential to enhance
proliferation and/or function in human islets. Examining
the therapeutic potential for PTHrP in human islets is
especially signiﬁcant given that PTHrP(1-36) is well estab-
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osteoporosis (15,16), demonstrating the safety of this
peptide as a future therapeutic agent.
RESEARCH DESIGN AND METHODS
Human islets, cell culture, and transduction with adenovirus. Human
islets were obtained from donors of both sexes, of ages ranging from 5t o7 0
years and with a majority being in the 20–50 year range, and with purity
ranging from 50–95%, through the Islet Cell Resource Centers (ICRs) and
Juvenile Diabetes Research Foundation Basic Science Islet Distribution
Programs. Human kidney cell lines, HKC8, and 293 with or without human
PTH1R cDNA were used as controls for PTH1R expression. Adenovirus (Ad)
constructs with cDNAs were generated (8) including those for -galactosidase
(LacZ), Cre recombinase, and green ﬂuorescent protein, which were used as
controls.
Proliferation. For cell-cycle analysis, human islets transduced with Ad
constructs for 72 h were dispersed into single cells and 10,000 cells were
analyzed on a BD LSR II ﬂow cytometer (Becton Dickinson Biosciences, San
Jose, CA). Data analysis was performed using Modﬁt LT 3.0 software (Verity
Software House, Topsham, ME). -cell proliferation was analyzed on either
Ad-transduced or peptide-treated dispersed human islet cultures stained for
DAPI, bromodeoxyuridine (BrdU), and insulin using Olympus Fluoview
Confocal or Olympus Provis Fluorescence microscopes (8).
Insulin release and content. Insulin release from uninfected, PTHrP(1-36)
treated, and Ad-transduced islets was measured in triplicate from human islets
either transduced with Ad constructs for 24 h or treated with 100 nmol/l of
PTHrP(1-36) for 24 h for insulin content or 30 min for GSIS (8). Brieﬂy,
uninfected or islets transduced with Ad for 24 h were preincubated in
Krebs-Ringer bicarbonate buffer supplemented with 10 mmol/l HEPES, 1%
BSA, and 5 mmol/l glucose for1ha t37°C in a 5% CO2 incubator. After washing
the islets once with the same solution, groups of 15 islet equivalents (IEQs) for
each condition were incubated in 1 ml fresh Krebs-Ringer bicarbonate buffer
plus 1% BSA and 5.5 or 22 mmol/l glucose. PTHrP peptide or vehicle was
added to the islets at the same time as the glucose and incubated for 30 min,
after which buffer was removed and frozen at 20°C until insulin measure-
ment by radioimmunoissay (RIA) (Linco Research, St. Louis, MO). Islets were
then digested overnight in NaOH at 37°C, and protein was measured by the
Bradford method after neutralization with HCl. Results are expressed as a
percentage of insulin concentration obtained with uninfected islets incubated
at 5.5 mmol/l glucose. Insulin content was measured by radioimmunoassay on
acid ethanol extracts of human islets either transduced with Ad-control or
Ad-PTHrP or treated with vehicle or 100 nmol/l of PTHrP(1-36) peptide for 24h
(8,17).
Gene expression. Gene expression in whole islets was analyzed by real-time
PCR performed on an ABI 7300 System and Western blot analysis on 20–50 g
extracts using the Image J program (NIH) for quantitative densitometry (8).
PTHrP(1-36) was quantitated using an immunoradiometric assay or an enzyme
immunoassay (Peninsula Laboratories, San Carlos, CA).
Statistical analysis. The data are expressed as the mean  SE. Statistical
signiﬁcance considered at P  0.05 was determined by an unpaired two-tailed
Student’s t test or a one-way ANOVA with Tukey’s honestly signiﬁcant differ-
ence post hoc test. Additional details regarding research design and methods
are available in an online appendix (http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1796/DC1).
RESULTS
PTH1R and PTHrP expression in human islets. PTHrP
mRNA and protein are expressed in human islets and
insulinomas (5,13,14). However, whether the receptor for
PTHrP, PTH1R, is expressed in human islets is unknown.
We analyzed the expression of PTH1R mRNA by real-time
PCR in human islets using HKC8, a human kidney cell line
with high PTH1R expression, as a positive control and 293
cells that lack PTH1R expression as a negative control.
PTH1R mRNA is clearly detectable in human islets (Fig.
1A), as is PTH1R protein, measured by Western blot (Fig.
1B). Importantly, PTH1R is expressed in human -cells,
demonstrated by costaining of human islet cell cultures for
PTH1R and insulin (Fig. 1C).
To overexpress PTHrP in human islets, an Ad construct
containing hemagglutinin (HA)-tagged human PTHrP
cDNA was transduced into islets. Ad-PTHrP–transduced
human islets display increased PTHrP expression relative
to uninfected and Ad-LacZ–transduced islets as demon-
strated by Western blot using PTHrP antibody (Fig. 1D).
Furthermore, PTHrP overexpression did not result in
downregulation of PTH1R expression in human islets (Fig.
1B) compared with uninfected or Ad-LacZ–transduced
islets (Fig. 1B). Since PTHrP is a secreted protein, we
measured its concentration in medium from human islets
transduced with Ad-PTHrP or Ad-LacZ. There was signif-
icant accumulation of PTHrP, 600 pmol/l, in medium
from Ad-PTHrP–infected islets versus Ad-LacZ–infected
islets (4 pmol/l) (Fig. 1E). Finally, PTHrP is expressed in
-cells of Ad-PTHrP–transduced human islet cell cultures
demonstrated by coimmunostaining with HA and insulin
antibodies (Fig. 1F).
PTHrP increases human -cell proliferation without
causing dedifferentiation. We examined the effect of
PTHrP overexpression on human -cell proliferation by
costaining human islet cell cultures transduced with Ad-
PTHrP or Ad-control with BrdU and insulin antibodies
(Fig. 2A). There was a signiﬁcant, approximately threefold,
increase in human -cell proliferation induced by PTHrP
compared with Ad-control–transduced or uninfected hu-
man islet cell cultures (Fig. 2B).
Based on studies in rodent -cells, we evaluated
whether secreted PTHrP is required for human -cell
proliferation by transducing human islets with Ad-SP,
a HA-tagged nonsecretory PTHrP mutant that lacks the
SP. As expected, secreted PTHrP levels in the medium
were much lower in Ad-SP– (22 pmol/l) versus Ad-
PTHrP–transduced (600 pmol/l) human islets (Fig. 1E).
However, PTHrP levels in islet extracts from Ad-SP
were at least comparable with Ad-PTHrP–transduced
human islets (Fig. 1D). Moreover, PTHrP was expressed
in the -cells of Ad-SP–transduced human islet cul-
tures as shown by HA and insulin costaining (Fig. 1F).
Despite abundant intracellular PTHrP, Ad-SP did not
stimulate proliferation of human -cells relative to
uninfected and Ad-control–infected islet cells (Fig. 2B),
demonstrating that secreted PTHrP is important for
mediating human -cell proliferation.
To determine which speciﬁc secretory form of PTHrP
induces human -cell proliferation, human islet cultures
were treated for 24 h with 100 nmol/l of either amino-
terminal PTHrP(1-36) or mid-region PTHrP(38-94) peptide.
There was a signiﬁcant twofold increase in human -cell
proliferation only with PTHrP(1-36) and not with PTHrP
(38–94) (Fig. 2B). The concentration of PTHrP(1-36) re-
maining in the culture medium of Ad-transduced and
peptide-treated human islet cell cultures was measured at
the end of the experiments. Cells treated with vehicle or
Ad-control had undetectable PTHrP(1-36), whereas Ad-
PTHrP–transduced cells had 469.8  57.4 pg/ml (117.5
pmol/l) and PTHrP(1-36)–treated cells had 245.1  20.6
ng/ml (61.25 nmol/l) of PTHrP(1-36) in the culture media
(n  4–5 human islet cultures).
Since induction of proliferation of human -cells can
lead to their dedifferentiation (17), we examined mRNA
transcripts encoding differentiation markers in human
islets treated with vehicle or PTHrP(1-36). There was no
change in transcripts encoding islet hormones (insulin,
glucagon, and somatostatin), glucose sensors (Glut-2
and glucokinase), or transcription factors important for
-cell differentiation and function (Pdx1, MafA, MafB,
Nkx6.1, Nkx2.2, NeuroD, and Isl1) with PTHrP(1-36)
treatment (Fig. 2C), suggesting that PTHrP does not
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ined the effect of PTHrP on insulin content in human
islets. Either transduction with Ad-PTHrP or treatment
with PTHrP(1-36) for 24 h did not affect the insulin
content in islets (Fig. 2D).
PTHrP enhances GSIS in human islets. Whether
PTHrP affects human -cell function was evaluated by
measuring insulin secretion from human islets transduced
for 24 h with Ad-PTHrP or treated for 30 min with
PTHrP(1-36) peptide. There was no change in basal insulin
secretion at 5.5 mmol/l glucose, and there was a small
(27%) but not signiﬁcant increase in insulin secretion at 22
mmol/l glucose from Ad-PTHrP – versus Ad-control–trans-
duced islets (Fig. 2E), suggesting that Ad-PTHrP does not
negatively impact human -cell function. On the other
hand, PTHrP(1-36) peptide caused a signiﬁcant increase in
insulin secretion at 5.5 mmol/l glucose (36%), with a
further enhancement at 22 mmol/l glucose (67%) over
control islets (Fig. 2F). Thus, PTHrP(1-36) enhances insu-
lin secretion in human islets at both physiological and
pathophysiological glucose concentrations.
PTHrP increases expression of the late G1/S cell
cycle activators cyclin E and cyclin-dependent kinase
2 in human islets at the posttranscriptional level. To
begin to assess the molecular mechanisms of PTHrP-
induced human -cell proliferation, we measured expres-
sion of the G1/S cell cycle regulators. There was no
signiﬁcant change in the level of mRNA expression of any
of the cyclins (cyclin D1–3, E1–2, and A1–2), cyclin-
dependent kinases (cdks) (1,2,4,6), cyclin inhibitory pro-
teins/kinase inhibitory proteins (CIP/KIP) (p21, p27, and
p57) or the inhibitor of kinase (INK) (p16, p18, and p19)
family of inhibitors examined with PTHrP(1-36) treatment
(Fig. 3A).
However, given that cell cycle molecules could be
regulated posttranscriptionally, we examined the effect of
PTHrP(1-36) on the expression of G1/S cell-cycle proteins
by Western blot. There was no change in expression of the
early G1/S cell-cycle activators cyclins D1/3 or cdk4/6 or in
the INK and CIP/KIP inhibitors p16, p18, p21, p27, and p57
(Fig. 3B). In contrast, the late G1/S cell cycle activator
FIG. 1. PTH1R and PTHrP expression in human islets. A: PTH1R mRNA expression measured by real-time PCR in three human islet preps
(H1–H3); HKC8, a human kidney proximal tubule cell line, used as positive control; and the human embryonic kidney cell line 293, used as
negative control. Quantitation is shown as log of Ct using actin as the housekeeping control gene. B: Western blot analysis of PTH1R and actin
expression in a positive () control line (293 cells stably transfected with human PTH1R cDNA) and two human islet preps (H1 and H2)
uninfected (U) or transduced with Ad-LacZ (L) or Ad-PTHrP (P). The line divides samples run on two different gels. C: Photomicrograph of human
islet cell cultures costained for nuclear DAPI (blue), PTH1R (green), and insulin (red). D: Representative Western blot analysis of PTHrP and
actin in human islets either uninfected (U) or transduced with Ad-LacZ (L), Ad-PTHrP (P), or Ad-SP mutant (S). The line divides samples from
different regions run on the same gel. E: Quantitation of PTHrP(1-36) by immunoradiometric assay in medium collected after 48 h of transduction
of human islets with adenoviral constructs containing LacZ, PTHrP, or SP sequences (n  2 islet preparations). F: Representative images of
human islet cell cultures transduced with Ad-LacZ, Ad-PTHrP, or Ad-SP and costained for DAPI (blue), insulin (green), and HA (red). (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 2. PTHrP increases human -cell proliferation and function without causing dedifferentiation. A: Representative confocal images of human islet cell
cultures transduced with Ad-control (I) or Ad-PTHrP (II–IV) and costained for insulin (green, panel b), BrdU (red, panel c), and DAPI (blue, panel d). The
merged images of all three stainings are shown in panel a, merge for DAPI and BrdU in panel e, and merge for insulin and BrdU in panel f. B: Quantitation
of the percentage of BrdU-positive -cells from human islet cell cultures uninfected (UI) or transduced with the adenovirus (AdV) constructs control (ctrl),
PTHrP, or SP for 72 h or treated with 100 nmol/l of either 1-36 or 38-94 PTHrP peptides for 24 h. There was a signiﬁcant two- to threefold increase in -cell
proliferation in PTHrP-transduced and 1-36–treated vs. Ad-control–transduced or uninfected control islet cells. Basal rate of -cell proliferation in uninfected
controls was 0.08 0.03% (n4–11 individual human islet preps at least in duplicate). *P<0.05 vs. uninfected or Ad-control by Student’s ttest; #P<0.001
vs. Ad-control or Ad-SP and &P < 0.01 vs. UI or 38-94 by one-way ANOVA. C: Expression of differentiation markers by real-time PCR from human islets
treated for 24 h with vehicle control (Ctrl) or PTHrP(1-36) peptide (gray bars). PCR cycles for each gene were compared, with actin used as an internal
control. The graph is depicted as fold over control, with values from vehicle-treated islets taken as 1 (n  4–7 human islet preparations in duplicate). D:
Insulin content per IEQ in extracts of human islets treated with vehicle (veh) or 100 nmol/l PTHrP(1-36) peptide or transduced with Ad-control (Ctrl) or
Ad-PTHrP for 24 h (n  5 human islet preparations in triplicate). E and F: Insulin secretion measured at 5.5 and 22 mmol/l glucose from human islets
transduced with Ad-control or Ad-PTHrP for 24 h (E) and treated with vehicle or 100 nmol/l PTHrP(1-36) peptide for 30 min (F). Insulin secretion is depicted
as percentage of vehicle-treated control at 5.5 mmol/l glucose, which was 455.4 109.3 pg/g protein in 30 min. n7–8 human islet preparations in triplicate.
*P < 0.05 vs. insulin secretion at 5.5 mmol/l glucose with the same treatment; #P < 0.05 vs. insulin secretion at equivalent glucose concentrations of control.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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were signiﬁcantly increased, by twofold, in PTHrP-treated
human islets.
Overexpression of cyclin E and cdk2 enhances human
-cell proliferation. To ascertain whether expression of
cyclin E and/or cdk2 per se can drive human -cell
proliferation, these proteins were overexpressed in human
islets by transduction with Ad-cdk2/Ad-cyclin E, relative to
uninfected and Ad-control–transduced islets (Fig. 4A).
Proliferation measured by ﬂow cytometry (Fig. 4B) re-
vealed a signiﬁcant 2.5-fold increase in the percentage of
cells in the S-phase of the cell cycle in Ad-cdk2/Ad–cyclin
E–transduced whole human islets compared with unin-
fected or Ad-control–transduced human islets (Fig. 4C),
demonstrating increased islet cell proliferation.
To independently conﬁrm these observations and to
demonstrate whether human -cell proliferation was in-
duced by cyclin E and/or cdk2, staining for insulin, BrdU,
and DAPI was performed on human islet cultures (Fig.
4D). Expression of cdk2 alone did not increase human
-cell proliferation. However, expression of cyclin E alone
caused a signiﬁcant ﬁvefold increase in human -cell
proliferation compared with control cells. Cyclin E and
cdk2 together caused a substantive synergistic 16-fold
increase in human -cell proliferation over cells trans-
duced with equivalent multiplicity of infection (MOI) of
control virus and also a signiﬁcant increase over cells
transduced with Ad-cdk2 or Ad-cyclin E alone (Fig. 4E).
DISCUSSION
This study documents for the ﬁrst time that PTHrP can
enhance human -cell growth and function. The major
novel ﬁndings of this study are as follows: 1) The PTHrP
receptor is present in human -cells. 2) Overexpression of
PTHrP causes a signiﬁcant threefold increase in human
-cell proliferation without negatively impacting function.
3) The secreted amino terminus 1-36 peptide of PTHrP is
sufﬁcient to induce replication without causing signiﬁcant
dedifferentiation of human -cells. 4) PTHrP(1-36) not
only increases proliferation but simultaneously enhances
human -cell function, as evidenced by a signiﬁcant in-
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FIG. 3. PTHrP increases expression of cyclin (cyc) E and cdk2 proteins but not mRNA in human islets. A: Expression of G1/S cell cycle regulators
by real-time PCR from human islets treated for 24 h with vehicle control (Ctrl) or PTHrP(1-36) peptide (gray bars). PCR cycles for each gene were
compared, with actin used as an internal control. The graph is depicted as fold over control, with values from vehicle-treated islets taken as 1 (n 
4–7 human islet preparations in duplicate). B: Representative Western blot analysis of the G1/S cell cycle activators and inhibitors from human
islets treated for 24 h with vehicle (veh) or PTHrP(1-36) using actin or tubulin as the internal housekeeping (HK) gene control. Quantitation of
the ratio of cyclin E/HK (C) and cdk2/HK protein (D) shows a signiﬁcant increase in both these proteins in PTHrP(1-36)–treated islets vs. control
(veh), depicted as 100%. *P < 0.05 (n  4–9 human islet preparations).
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enhances human -cell proliferation. A: Western blot
analysis of human islets uninfected (UI) or transduced
with Ad-control (Ad-ctrl) or a combination of Ad-cdk2/
Ad-cyclin E for expression of cdk2, cyclin E, and actin
as an internal control. The line divides samples from
different regions on the same gel. Representative cell
cycle phase distribution proﬁles (B) and percentage of
cells in S-phase (C) of the cell cycle of uninfected,
Ad-control, or Ad-cdk2/Ad-cyclin E–transduced human
islet cells analyzed using ﬂow cytometry. The percent-
age of cells in the G1-phase was reduced, although not
signiﬁcantly, in Ad-cdk2/Ad-cyclin E–transduced (G1:
91.1  1.0%, G2/M: 5.4  1.2%) vs. uninfected (G1:
93.0  1.3%, G2/M: 5.4  1.2%) and Ad-control–trans-
duced (G1: 94.0  1.0%, G2/M: 4.6  0.9%) human
islets, whereas the percentage of cells in S-phase of the
cell cycle in Ad-cdk2/Ad-cyclin E–transduced human
islets was signiﬁcantly greater compared with unin-
fected or Ad-control–transduced human islets (n  10
human islet preparations). D: Representative images
of human islet cell cultures transduced with 100 MOI of Ad-control, 50 MOI of Ad-control plus 50 MOI of Ad-cdk2, or 50 MOI of Ad-cyclin E and
50 MOI each of Ad-cdk2 and Ad-cyclin E and costained for DAPI (blue), insulin (green), and BrdU (red). Arrows indicate BrdU and
insulin-positive cells. E: Quantitation of the percentage of BrdU-positive -cells from human islet cell cultures transduced with the Ad constructs
described for C. There was a signiﬁcant 5-fold and 16-fold increase in -cell proliferation in cyclin E– and cdk2/cyclin E– vs. Ad-control–
transduced islet cells, respectively. Basal rate of -cell proliferation in controls was 0.17  0.06%, taken as 100%. n  9; 3 human islet
preparations in triplicate. *P < 0.01 vs. control by Student’s t test; #P < 0.001 vs. the other three groups by one-way ANOVA. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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mmol/l) and pathophysiological (22 mmol/l) glucose con-
centrations. 5) PTHrP(1-36) speciﬁcally increases expres-
sion of the late G1/S cell cycle activators cyclin E and cdk2
at the posttranscriptional level in human islets. 6) overex-
pression of cyclin E but not cdk2 signiﬁcantly increases
human -cell replication. 7) More importantly, the combi-
nation of these two molecules has a substantive synergis-
tic effect on human -cell proliferation.
The current study, together with previous work (6–
8,10–12), establishes PTHrP as a factor that enhances
proliferation and function in primary -cells from both
rodent and human islets. Whereas in some instances
activation of human -cell replication may induce dedif-
ferentiation (17), in others—e.g., in this study and with
overexpression of cdk6/cyclin D1 or constitutively active
Akt (18,19)—induction of human -cell proliferation main-
tains or even augments -cell function. Based on studies in
rodent islets (12), it is likely that PTHrP(1-36) may en-
hance insulin secretion in human islets through activation
of the cAMP pathway.
PTHrP enhances proliferation in numerous cell types.
This mitogenic activity is associated with changes in cyclin
D1 transcription, activation of cyclin E/cdk2 kinase activ-
ity, or reduction of p57 or p27 inhibitors (20–22). In human
-cells, we found that PTHrP(1-36) is sufﬁcient to induce
proliferation, causing an increase in expression at the
posttrancriptional level of two activators of the late phase
of the G1/S cell-cycle check point, cdk2 and cyclin E.
PTHrP regulates the stability of p27 in smooth-muscle
cells, as well as the androgen receptor in prostate cancer
cells, through the proteosomal degradation pathway
(21,23). Cyclin E protein is also tightly regulated through
proteasome-mediated degradation by the E3 ubiquitin
ligases (24). Whether PTHrP affects cyclin E stability
through this pathway in human -cells requires further
investigation.
There is ample evidence that activators of the early
phase of the cell cycle, cyclin Ds and cdk4/cdk6, regulate
rodent -cell proliferation and can induce human -cell
proliferation (18,25). However, whether activators of the
late phase of the cell cycle, cyclin E and cdk2, are
important for and can induce human -cell proliferation is
not known. Now, we demonstrate for the ﬁrst time that
cyclin E, both alone and together with cdk2, signiﬁcantly
enhances human -cell proliferation, suggesting that cy-
clin E may be one of the limiting factors in proliferation of
human -cells.
Understanding the regulation of, and elucidating thera-
peutic mechanisms to enhance, human -cell proliferation
and function is critical for the long-term treatment of
diabetes. This study shows that a small amino terminus
peptide of PTHrP is capable of enhancing both prolifera-
tion and function in human -cells in vitro. Further, it
identiﬁes two cell-cycle activators as likely downstream
targets of PTHrP. Cyclin E and cdk2 together have pro-
nounced effects on human -cell proliferation and, there-
fore, have the potential to be harnessed to enhance human
-cell growth ex vivo. The promise for PTHrP(1-36) as a
therapeutic agent for diabetes is especially attractive,
given that this peptide has been shown to be both safe and
effective for the treatment of osteoporosis (15,16) and that
PTHrP(1-36) in the 100 pmol/l range, a concentration that
is likely transiently induced in humans treated with toler-
able doses of PTHrP(1-36) (15,16), is sufﬁcient to enhance
human -cell proliferation in vitro. Future studies will
determine whether this peptide can be used either ex vivo
or in vivo to improve human islet growth and function.
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